Marrow has announced a $2 million pre-seed round to expand the infrastructure connecting AI agents with insurance companies. The funding was announced on 22 October by lead investor Insurtech Gateway, with Seed X, Leo Capital, Portfolio Ventures and angel investors also participating. It is an early-stage company financing round, not an insurance product launch.
The money is intended to support engineering and commercial recruitment in London, bring more retail and commercial insurance providers onto the platform, and develop the first full version of the Agent Mediated Insurance standards with an industry working group. That standards work remains unfinished: the investor says the industry comment period runs until 13 November.
Insurtech Gateway also says Marrow has signed further carriers, brokers and managing general agents. Its announcement does not identify those additional customers or quantify the revenue generated by the expanding relationships.
Existing deployment, new hiring
Leo Capital, one of the investors, says Marrow has been in production with Aviva since March 2026, following procurement, information security, legal and data-protection reviews. This is an investor account of an existing deployment, rather than an announcement that a new Aviva contract was signed alongside the funding round.
Aviva separately named Marrow in its own 29 September update on its relationship with Founders Factory. The insurer described the company as connecting AI systems such as ChatGPT, Claude and Gemini with insurer pricing, underwriting and policy-administration systems. That statement confirms the relationship independently of the fundraising announcement, although it does not put a value on the commercial arrangement.
Marrow’s careers page, checked on 28 October, lists London-based full-time openings for an AI platform engineer, an applied AI engineer and a founding go-to-market lead. The descriptions span the software runtime, integration inside carrier systems and commercial work. These vacancies give a more concrete indication of the functions the company is recruiting for than a general promise to expand its team.
The company was founded by Tim Graham and Adam Mesout. Leo Capital describes Graham’s background in insurance distribution and AI product development, while Mesout combines actuarial training with engineering. The investor’s thesis is that AI could become another insurance distribution channel. That expectation is not evidence of future customer demand or guaranteed commercial returns.
Marrow identifies itself as a trading name of Project Malcolm Limited and says it is not an insurance company. Its technology role should therefore not be confused with the role of the carrier providing cover. The financing announcement is not an offer to buy a policy or an assurance about any insurer’s products.
The standards work still to be completed
The published AMI overview carries a 1 September 2026 version date and is labelled a working draft. Its description of current production is narrower than fully autonomous insurance purchasing: consumer AI can generate regulated quotes, with customers then handed to the carrier’s own journey to complete the purchase. The draft describes a broader proposed framework, not proof that every proposed capability is already deployed.
The implementation guidance leaves pricing and risk appetite with insurers. It calls for material insurance facts to come from authoritative sources, with disclosures and an audit record built into the process. For Marrow’s expansion, the relevant development task is connecting these requirements to provider systems, rather than simply adding a conversational interface in front of an insurance website.
The draft also separates a default model requiring fresh human confirmation for transactions from a delegated model based on a separate, limited authorisation. The latter is subject to defined scope and limits, not blanket permission for an AI agent to act. These are proposed standards requirements; the reviewed sources do not establish that every Marrow deployment implements that delegated model.
Several implementation materials remain outstanding. The standards site says canonical machine-readable schemas, tool definitions, a conformance-log format and a discovery document have not yet been published. They are planned for a later release. Its conformance approach is also self-declaration by an implementer, not certification or regulatory approval. These distinctions leave identifiable development work between the current draft and the fuller framework the financing is intended to support.
Related Dalimss News reporting covers UK Sovereign AI investment and procurement and BridgeAI deployment grants. Those are separate public programmes, not sources of the Marrow funding reported here.
The standards discussion adapts the Agent Mediated Insurance standards, stewarded by Marrow on behalf of the AMI working group, under CC BY 4.0. Dalimss News has condensed and reworded the material. Attribution does not imply endorsement.
